Veradigm Inc. (MDRX) Research

Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.

Market snapshot

Symbol
MDRX
Price
$4.80
Day change
0.00%
Market cap
$815.2M
P/E ratio
-7.16x
52-week range
3-6
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Next earnings
in 1 month
Analyst price target
$16.17

Peer companies

  • Arjo AB (publ) (ARRJF)
  • EL.En. S.p.A. (ELEAF)
  • Valneva SE (INRLF)
  • LifeTech Scientific Corporation (LFTSF)
  • Panamera Holdings Corporation (PHCI)
  • Safilo Group S.p.A. (SAFLF)
  • SMS Co., Ltd. (SMSZF)
  • Tong Ren Tang Technologies Co. Ltd. (TGRNF)

Recent insider activity

  • Sacks Jonathan S — A-Award (42507 shares) on 2026-06-01
  • STONEHILL CAPITAL MANAGEMENT LLC — A-Award (42507 shares) on 2026-06-01
  • Greyenbuhl Christian — trade (0 shares) on 2026-05-27
  • Jacobson Eric L — F-InKind (1584 shares) on 2026-05-10
  • Jacobson Eric L — A-Award (75000 shares) on 2026-05-01

Open Veradigm Inc. (MDRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.